Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pinnacle Biologics has entered into an agreement with Chiltern International for the activities of pharmacovigilence/safety reporting and medical information services for western Europe.
Subscribe to our email newsletter
James Miller, president and CEO of Pinnacle Biologics, said: “The completion of the Chiltern agreement represents a significant step in the process of offering a full range of services and solutions to the pharmaceutical/biotechnology companies that we currently represent or will partner with in the future. We are proud to be associated with Chiltern.”
Glenn Kerkhof, CEO of Chiltern, said: “Chiltern is extremely excited about expanding our service portfolio to meet the Pinnacle Biologics unique pharmocovigilence, safety and medical information requirements and help accelerate the commercialization of pharmaceutical products that are promoted and distributed by Pinnacle.”